Financed by European Union – EU Projects

Project name: Audiocracker – Glazba i Umjetna inteligencija
Project code: NPOO.C1.1.2.R2-I3.02.0494
Co-financed by EU: 124.278,38 €
Total value of the project: 146.209,76 €
Project timeframe: 01.12.2022. – 01.12.2024.
Contact: Dražen Horvat, drazen.horvat@atmc.ai
Link to project: https://www.stemjam.app/
Short description: Audio Separation is a project that applies advanced deep neural networks to accurately separate instruments and vocals from musical recordings (so-called Musical Source Separation). Thanks to models trained on a large dataset, this technology recognizes the specific characteristics of each sound, allowing for clear separation in the final recording.
As the final product, the Stem&Jam platform offers the extraction of individual sound sources, the removal of instruments, customized post-separation processing, and exporting to formats suitable for further use. Additionally, the platform provides tools for learning to play instruments, including recording and comparing performances, tempo control, defining sections, and repeating selected passages.

Project name: ProSTRAT-AI – Artificial Intelligence to STRATify Prostate cancer patients and guide intervention
Project code: 2022-17594/NP/DANUBE 2022 CALL ProSTRAT-A
Total value of the project: 986.984,00 €
Project timeframe: 01.01.2023. – 01.01.2026.
Contact: Dražen Horvat, drazen.horvat@atmc.ai
Link to project: https://www.prostrat-ai.eu/
Short description: ProSTRAT-AI is an innovative diagnostic tool that leverages artificial intelligence to enhance prostate cancer care. By accurately stratifying patients, it guides personalized interventions for optimal outcomes. Supported by international collaboration, ProSTRAT-AI is at the forefront of medical innovation, aiming to revolutionize prostate cancer diagnostics.
has context menu

Project name: MULTIR
Contact: Dražen Horvat, drazen.horvat@atmc.ai
Link to project: https://www.multir.eu/
Short description: The MULTIR Consortium aims to study tumor-host interactions across various tumor types and patient characteristics, collecting extensive clinical and molecular data to enhance understanding of treatment response mechanisms. Collaboration among specialists enables comprehensive analysis, with a focus on investigating immune-rich tumor types such as bladder, lung, and melanoma to identify potential targetable characteristics.